Chief executive officer

How well did Sanofi perform in 2011 and what were some
of the key highlights?

2011 was a key year in transforming Sanofi. We successfully acquired and integrated Genzyme, our growth platforms recorded double-digit growth[…], we delivered cost savings as planned and delivered on innovation. Our late stage development portfolio holds significant value with five new medicines submitted for registration in 2011 and a sixth will be submitted in the first half of 2012.

You’ve been pursuing the same strategy since 2008…

Yes and we can see the fruits of this consistency in building a company based on sustainable growth. By increasing innovation in R&D, maximizing external opportunities and adapting the company for future challenges and opportunities, we now have strong growth platforms with minimal patent exposure post 2013.

Read more of the interview…